Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €426.00 EUR
Change Today -0.55 / -0.13%
Volume 0.0
RGO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 2:18 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for regeneron pharmaceuticals (RGO)

This company's debt to total capital ratio, at 15.26%, is in-line with the Biotechnology industry's norm. Additionally, there are enough liquid assets to satisfy current obligations. Cash Collection is a strong suit as the company is more effective than most in the industry. As of the end of 2014, its uncollected receivables totaled $1.0B USD, which, at the current sales rate provides a Days Receivables Outstanding of 127.66. Last, Regeneron Pharmaceuticals, Inc. is among the least efficient in its industry at managing inventories and has been consistently getting worse. At the most recent fiscal year end there were 24.63 days of this company's Cost of Goods Sold tied up in Inventories.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Reclassified
Dec 31
2012
Dec 31
2013
Dec 31
2014
4 Year
Trend
Assets    
Cash and Equivalents483.6230.3535.6648.7
Short-Term Investments43.377.8158.4251.8
TOTAL CASH AND SHORT TERM INVESTMENTS526.9308.1694.0900.5
Accounts Receivable103.0693.1955.01,017.4
TOTAL RECEIVABLES103.0693.1955.01,017.4
Inventory16.628.670.4128.9
Prepaid Expenses19.228.033.071.5
Deferred Tax Assets, Current--148.144.749.2
TOTAL CURRENT ASSETS665.81,206.01,796.92,167.5
Gross Property Plant and Equipment526.1560.5748.61,228.3
Accumulated Depreciation-158.1-180.5-221.6-254.0
NET PROPERTY PLANT AND EQUIPMENT368.0379.9527.0974.3
Long-Term Investments275.9271.2389.9460.2
Deferred Tax Assets, Long Term--192.0231.9266.9
Deferred Charges, Long Term5.7------
Other Long-Term Assets8.331.35.33.0
TOTAL ASSETS1,323.62,080.52,951.03,871.8
    
LIABILITIES & EQUITY    
Accounts Payable27.738.961.999.5
Accrued Expenses67.972.4189.0384.7
Current Portion of Long-Term Debt/Capital Lease1.01.4----
Current Portion of Capital Lease Obligations1.01.4----
Other Current Liabilities, Total----0.996.4
Unearned Revenue, Current51.650.847.074.0
TOTAL CURRENT LIABILITIES148.3163.6298.8654.7
Long-Term Debt275.0296.5320.3146.8
Capital Leases162.0159.4184.3310.9
Unearned Revenue, Non-Current248.6208.3184.2176.3
Other Non-Current Liabilities3.97.311.340.9
TOTAL LIABILITIES837.9835.1998.91,329.5
Common Stock0.10.10.10.1
Additional Paid in Capital1,754.81,763.52,045.92,404.1
Retained Earnings-1,267.3-517.1-92.7255.4
Treasury Stock-------169.5
Comprehensive Income and Other-1.9-1.2-1.252.3
TOTAL COMMON EQUITY485.71,245.41,952.12,542.3
TOTAL EQUITY485.71,245.41,952.12,542.3
TOTAL LIABILITIES AND EQUITY1,323.62,080.52,951.03,871.8
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGO:GR €426.00 EUR -0.55

RGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $116.32 USD +0.40
Incyte Corp $101.00 USD +2.72
Pharmacyclics Inc $254.75 USD +0.24
UCB SA €62.90 EUR -0.55
Vertex Pharmaceuticals Inc $126.30 USD +0.70
View Industry Companies
 

Industry Analysis

RGO

Industry Average

Valuation RGO Industry Range
Price/Earnings 100.0x
Price/Sales 17.0x
Price/Book 18.9x
Price/Cash Flow 137.1x
TEV/Sales 16.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.